Unit of Ophthalmology, Department of Surgery, Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico, Milan, Italy.
Unit of Otolaringology, Department of Surgery, Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico, Milan, Italy.
Thyroid. 2023 Jun;33(6):743-751. doi: 10.1089/thy.2022.0564. Epub 2023 May 22.
Current guidelines suggest high-dose steroids as first-line treatment for dysthyroid optic neuropathy (DON). When steroids fail, decompressive surgery is mandatory. We conducted a single-center, retrospective cohort study in a tertiary care combined Thyroid-Eye clinic in Milan, Italy. We studied 88 orbits of 56 patients that were submitted to surgical orbital decompression to treat DON from 2005 to 2020. Of these, 33 orbits (37.5%) underwent surgery as first-line treatment for DON whereas the other 55 (62.5%) were decompressed after being unresponsive to very high-dose steroids. Previous orbital surgery, concurrent neurological or ophthalmologic diseases, or incomplete follow-up were considered as exclusion criteria from this study. Surgery was considered successful if no further decompression was needed to preserve vision. Pinhole best corrected visual acuity (p-BCVA), color sensitivity, automated visual field, pupil reflexes, optic disk and fundus appearance, exophtalmometry, and ocular motility were studied before and after surgery (1 week, 1, 3, 6, and 12 months). Activity of Graves' Orbitopathy (GO) was graded using a clinical activity score (CAS). Surgery was successful in 77 orbits (87.5%). The remaining 11 orbits (12.5%) needed further surgery to treat DON definitively. All parameters of visual function improved significantly at follow-up and GO inactivated (CAS <3) within 1 month. At 3 months, all 77 responding orbits had p-BCVA >0.63 whereas all of the 11 non-responding orbits had p-BCVA ≤0.63. Visual field parameters and color sensitivity were not associated with response to surgery. High-dose steroid treatment before surgery was associated with a better response rate (96% vs. 73%; = 0.004). Balanced decompression was associated with a higher response rate compared with medial wall decompression (96% vs. 80%; = 0.04). A significant inverse correlation was observed between final p-BCVA and the patient's age ( = -0.42; = 0.0003). Surgical decompression was found to be a very effective treatment for DON. In this study, all clinical parameters improved after surgery and further intervention was rarely needed.
目前的指南建议高剂量类固醇作为甲状腺眼病(DON)的一线治疗方法。当类固醇治疗无效时,减压手术是必需的。我们在意大利米兰的一家甲状腺眼病联合诊所进行了一项单中心回顾性队列研究。我们研究了 2005 年至 2020 年间因 DON 接受手术眶减压治疗的 56 例患者的 88 只眼眶。其中,33 只眼眶(37.5%)作为 DON 的一线治疗进行了手术,而另外 55 只眼眶(62.5%)在对超高剂量类固醇无反应后进行了减压。先前的眼眶手术、同时存在的神经或眼科疾病或不完整的随访被认为是本研究的排除标准。如果不需要进一步减压来维持视力,则认为手术成功。手术前后(1 周、1、3、6 和 12 个月)研究了小孔最佳矫正视力(p-BCVA)、颜色敏感度、自动视野、瞳孔反射、视盘和眼底外观、眼球突出度和眼球运动。使用临床活动评分(CAS)对 Graves 眼病(GO)的活动进行分级。77 只眼眶(87.5%)手术成功。其余 11 只眼眶(12.5%)需要进一步手术以确定治疗 DON。所有视觉功能参数在随访时均显著改善,GO 在 1 个月内失活(CAS<3)。在 3 个月时,77 只反应良好的眼眶的 p-BCVA>0.63,而 11 只无反应的眼眶的 p-BCVA≤0.63。视觉功能参数和颜色敏感度与手术反应无关。术前高剂量类固醇治疗与更高的反应率相关(96%比 73%;=0.004)。与内侧壁减压相比,平衡减压与更高的反应率相关(96%比 80%;=0.04)。最终 p-BCVA 与患者年龄呈显著负相关(=−0.42;=0.0003)。手术减压被发现是 DON 的一种非常有效的治疗方法。在这项研究中,手术后所有临床参数均得到改善,很少需要进一步干预。